Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME) (Frontier-1)

Kanghong Pharmaceutical

Status and phase: Completed; Phase 2; Phase 1

Conditions: Diabetic Macular Edema

Treatments: Biological: KH902

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01324869

KHSWKH902002

Details and patient eligibility

About

This study is designed to access the safety and efficacy of multiple injections of KH902 in patients with Diabetic Macular Edema (DME).

Full description

With improvement of our living standard, patients who suffered from Diabetes become more and more. As the investigators know, Diabetes can induce many ocular diseases leading to vision loss. And according to observations, DME is diagnosed as one main cause of vision loss in the patients with Diabetes.

As the results of many studies conducted previously, anti-VEGF drugs and anti-VEGF treatments show its effect and safety not only in treating AMD, but also in patients with DME. The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein. The previous clinical trials of KH902 show that KH902 is effective and safe in inhibiting the growth, migration, pullulation of vascular endothelial cells and neovascularization induced by VEGF. Due to these positive results, the investigators prepare to conduct a clinical trial to assess the safety and efficacy with intravitreal injection of KH902 in patients with DME.

Enrollment: 20 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed the Informed Consent Form and willing to comply with study procedures;

• 18 years old ≦ either gender ≦ 75 years old;

• Confirmed diagnosed with Type 1 diabetes or Type 2 diabetes based on the diabetes diagnosis criteria;

• Clinically significant DME:

  • Hard exudation within 500μm of the central foveal diameter accompanied with contiguous retina thickening;
  • The edema locates within 500μm of the central foveal diameter;
  • Retina thickening field > 1DD and within the 1DD central fovea.

• BCVA score of the study eyes between 78 and 19 letters, inclusively, and the BCVA score of fellow eyes ≥ 24 letters;

• Previous treatment of antidiabetic drugs within three months preceding the screening, and blood-glucose concentration is predicted to be unchanged and stable during the whole study.

Exclusion criteria

• Uncontrolled glaucoma in either eye;
• Currently active ocular inflammation or infection in either eye;
• Macular edema in the study eye was caused by other diseases rather than diabetes;
• Company with any other ocular conditions failing to prevent vision loss despite improving the macular edema;
• Any other ocular diseases which may cause macular edema or vision alteration during study phase;
• Retinal macular traction or macular epiretinal membrane in study eye;
• Refractive error equate or exceed 8 diopters of myopia in study eye
• Whole or regional retinal laser photocoagulation has been applied in study eye within 6 months preceding the screening;
• Previous anti-VEGF drug treatment in study eye;
• Intraocular or periocular injection of steroid drug within 6 months preceding the screening;
• Previous ophthalmologic operation within 3 months preceding the screening and/or planning to receive an ophthalmologic operation during the study.
• There is any potential for the study eye to receive the panretinal laser photocoagulation treatment during the study;
• Previous vitrectomy in study eye.
• Uncontrolled diabetes;
• Hypertensive patients with poorly controlled blood pressure;
• Uncontrolled systemic infectious diseases;
• Systemic immune diseases;
• History of allergy;
• Any uncontrolled clinical disorders;
• Pregnant or nursing women;
• Adopt one or more adequate contraception methods.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

Group A

Experimental group

Description:

Patients will receive an intravitreal injection of 0.5mg KH902 in the study eye at the first month, following the fixed injection, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.

Treatment:

Biological: KH902

Group B

Experimental group

Description:

Patients will receive continuously monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye; following the initial 3-month fixed-dosing phase of the trial, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.

Treatment:

Biological: KH902